Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
  • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
  • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
  • A61K38/095—Oxytocins; Vasopressins; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/23—Calcitonins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/26—Glucagons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/28—Insulins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1611—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
  • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

• the dry powders are preferably intended for pulmonary delivery by inhalation to treat certain disorders and/or diseases, including post-partum hemorrhaging.
• Isolated biological substances including, certain proteins and peptides can readily and completely lose functional activity, for example, by taking them out of - 20°C storage once.
• Other isolated proteins and peptides undergo significant degradation when stored at 4°C, without the addition of protease inhibitors.
• Most mammalian proteins and peptides degrade at a temperature greater than 43°C. It has been well established that at 55°C, most proteins undergo complete denaturation in about 1 -2 hours. In some cases, complete denaturation and destabilization of an isolated protein also occurs at room temperature.
• Due to the problems associated with oral drug delivery of drugs and in particular, biologically-derived products, drug delivery to the lungs has been explored.
• drugs delivered to the lungs are designed to have an effect on the tissue of the lungs, for example, vasodilators, surfactants, chemotherapeutic agents or vaccines for flu or other respiratory illnesses.
• Drug formulations for treating pulmonary diseases such as asthma are available by several methods, including, using nebulizers such as treatment with PULMOZYME ® , using metered-dose inhalers such as SYMBICORT ® , and dry powder inhalers such as ADVAIR DISKUS ® , PULMICORT FLEXAHER ®
• Other drugs, including nucleotide drugs have been delivered to the lungs because they represent a tissue particularly appropriate for treatment, for example, for genetic therapy in cystic fibrosis, where retroviral vectors expressing an effective adenosine deaminase are administered to the lungs.
• a pharmaceutical formulation comprising a dry powder for inhalation comprising a biologic molecule, wherein the biologic molecule comprises a peptide or a protein for systemic delivery using a dry powder inhalation system comprising an inhaler that can be used with a unit dose cartridge or capsule for multiple use, a single use inhaler with an integrally built-in container for single use, or a multidose inhaler provided with a plurality of doses integrally configured with the inhaler.
• a heat-stable pharmaceutical formulation comprising, a dry powder comprising a protein or a peptide and one or more pharmaceutically acceptable carriers and/or excipients, which formulations are stable at high temperatures and high humidity.
• the pharmaceutical formulation is stable for a long period of time at temperatures, for example, temperatures greater than 20°C, greater than 25°C, greater than 30°C, or greater than 35°C; and relative humid environments such as environments having a relative humidity greater than 5%, greater than 10%, greater than 30%, greater than 50%, greater than 60%, or greater than 70%; wherein the pharmaceutically acceptable carriers and/or excipients include, for example, buffers, salts, polymers, diketopiperazines and/or salts thereof, and the like.
• the dry powder compositions can optionally include surfactants such as polysorbates, for example, polysorbate 80 and Tween.
• the formulation comprises a dry powder comprising a peptide, including, for example, oxytocin, an oxytocin derivative or an analog thereof such as carbotecin; a buffer, and a monovalent or divalent cationic salt, and optionally a sugar and/or an amino acid.
• a peptide including, for example, oxytocin, an oxytocin derivative or an analog thereof such as carbotecin; a buffer, and a monovalent or divalent cationic salt, and optionally a sugar and/or an amino acid.
• the formulation comprises a dry powder comprising oxytocin, an oxytocin derivative, or an oxytocin analog; a buffer and/or a divalent cation or monovalent cation provided by a salt, including, zinc citrate, zinc acetate, disodium tartrate, mono-sodium tartrate, sodium citrate, disodium citrate, trisodium citrate, zinc chloride, calcium chloride, magnesium chloride, sodium hydroxide, and the like.
• the formulation further comprises one or more amino acids, including leucine, isoleucine, trileucine, cystine, arginine, lysine, methionine, and/or histidine.
• the monovalent cation in the formulation can include sodium, potassium and lithium.
• the formulation may be provided with citric acid.
• a dry powder composition comprising oxytocin, sodium citrate, including, monovalent, divalent or trivalent form, in an amount less than 40% (w/w), less than 30% (w/w), less than 20% (w/w), or less than 10% (w/w), and zinc chloride or zinc citrate in an amount less than 35% (w/w), less than 20% (w/w), or less than 10% (w/w) in the composition.
• the zinc chloride is used in an amount ranging from about 1 % to about 7% (w/w) of the composition.
• the zinc citrate is used in an amount ranging from about 9% to about 35% (w/w) of the composition.
• a dry powder composition comprising oxytocin, sodium tartrate, including, monovalent, or divalent form, in an amount less than 40% (w/w), less than 30% (w/w), less than 20% (w/w), or less than 10% (w/w), and zinc chloride or zinc citrate in an amount less than 35% (w/w), less than 20% (w/w), or less than 10% (w/w) in the composition.
• the zinc chloride is used in an amount ranging from about 1 % to about 7% (w/w) of the composition.
• the zinc tartrate is used in an amount ranging from about 9% to about 35% (w/w) of the composition.
• the dry powder composition comprises citrate salts in an amount ranging from 100 to 20 equivalents per mole of oxytocin, an oxytocin analog or derivative thereof; and the amount of zinc salts can range from 50 to 5 equivalents per mole of oxytocin in the composition.
• concentrated sodium citrate buffers were used as the source of citrate; wherein the citrate buffers had a concentration up to 0.1 M or 0.75 M and range in pH values of 4.0 to 6.5.
• the dry powder composition comprises oxytocin or an analog or derivative thereof; zinc and citrate, wherein the oxytocin, analog or derivative thereof is in an amount up to 200 IU in a single inhalable dose.
• the dry powder composition comprises 150 IU, 100 IU, 50 IU, 40 IU, 20 lU, 10 IU, 5 IU, 1 IU, 0.05 IU, or 0.005 IU of oxytocin, an analog or a derivative thereof in a single inhalable dose.
• a method of making a dry powder formulation comprising mixing or homogenizing a solution comprising a peptide or protein or analog thereof, wherein the solution comprises citrate salts in an amount ranging from 100 to 20 equivalents per mole of the peptide or protein; and an amount of zinc salts can range from 50 to 5 equivalents per mole of the peptide or protein or analog thereof in the composition.
• concentrated sodium citrate buffers were used as the source of citrate; and spray-drying a solution in a nitrogen gas chamber, comprising a peptide, protein, fragments thereof and/or analogs thereof, wherein the dry powder formulation comprises a mixture of the peptide, protein, fragments thereof and/or analogs thereof; a citrate or tartrate and a cationic salt at a pH ranging from pH 4.5 to pH 6.5, and wherein the cationic salt is a divalent cationic salt.
• Embodiments include a method for treating post-partum hemorrhaging comprising administering to a subject in need of treatment a dry powder formulation by inhalation, the composition comprising oxytocin, an analog thereof or derivative thereof; a citrate or tartrate and a source of a cation, including, zinc within 24 hours post-partum.
• the treatment comprises administrating one or more doses of the dry powder formulation described herewith immediately upon childbirth.
• a method of preventing post-partum hemorrhage comprising administering to a subject susceptible of post-partum hemorrhage a dry powder formulation comprising oxytocin, an analog thereof or derivative thereof; a citrate or tartrate, and a source of a cation, including, zinc within 24 hours or immediately after childbirth.
• the inhalation system is a high resistance inhaler for single dose usage.
• FIGs. 1A and 1 B are scanning electron micrographs of an amorphous dry powder formulation embodiment comprising 1 % oxytocin, 87% trehalose; 10% isoleucine and 10% polyvinylpirrolidone (PVP) at low (1A) and high magnification (1 B).
• PVP polyvinylpirrolidone
• FIG. 2A is a scanning electron micrograph of a control powder similar to FIG. 1 B at high magnification.
• FIGs 2B, 2C and 2D are scanning electron micrographs of an amorphous dry powder formulation embodiments comprising 1 % oxytocin; citrate and a zinc salt at high magnification and containing differing amounts of divalent zinc salts and citrate salts.
• FIG. 3 provides a graphic representation of data obtained from stability studies data for dry powder composition embodiments comprising 1 % oxytocin incubated at 40 °C and 75% relative humidity for a period of approximately 1 1 months compared to a control.
• FIG. 4 provides a graphic representation of data obtained from X-ray diffraction studies of dry powders showing amorphous content of the powders by their characteristic scan patterns.
• FIG. 5 is a graphic representation of dry powder samples from the stability studies wherein the samples contained divalent zinc salt and citrate salts at various concentrations.
• microparticle refers to a particle with a diameter of about 0.5 to about 1000 ⁇ , irrespective of the precise exterior or interior structure. Microparticles having a diameter of between about 0.5 and about 10 microns can reach the lungs, successfully passing most of the natural barriers. A diameter of less than about 10 microns is required to navigate the turn of the throat and a diameter of about 0.5 microns or greater is required to avoid being exhaled.
• RF respirable fraction
• RF respirable fraction
• a laser diffraction apparatus is used to determine particle size, for example, the laser diffraction apparatus disclosed in U.S.
• VMGD volumetric median geometric diameter
• Respirable fraction on fill represents the % of powder in a dose that is emitted from an inhaler upon discharge of the powder content filled for use as the dose, and that is suitable for respiration, i.e., the percent of particles from the filled dose that are emitted with sizes suitable for pulmonary delivery, which is a measure of microparticle aerodynamic performance.
• a RF/fill value of 40% or greater than 40% reflects acceptable aerodynamic performance characteristics.
• the respirable fraction on fill can be greater than 50%.
• a respirable fraction on fill can be up to about 80%, wherein about 80% of the fill is emitted with particle sizes ⁇ 5.8 ⁇ as measured using standard techniques.
• dry powder refers to a fine particulate composition that is not suspended or dissolved in a propellant, or other liquid. It is not meant to necessarily imply a complete absence of all water molecules.
• amorphous powder refers to dry powders lacking a definite repeating form, shape, or structure, including all non-crystalline powders.
• the dry powder is a relatively cohesive powder which requires optimal deagglomeration condition.
• the inhalation system provides a re-useable, miniature breath-powered inhaler in combination with single-use cartridges containing pre-metered doses of a dry powder formulation.
• a unit dose inhaler refers to an inhaler that is adapted to receive or comprises a single container comprising a dry powder formulation and delivers a single dose of a dry powder formulation by inhalation from the container to a user. In some instances multiple unit doses will be required to provide a user with a specified dosage.
• the inhaler is a dry powder inhaler, which can be disposable for single use, or reusable for multiple uses with a single unit dose container.
• a multiple dose inhaler refers to an inhaler having a plurality of containers, each container comprising a pre-metered dose of a dry powder medicament and the inhaler delivers a single dose of a medicament powder by inhalation at any one time.
• a "container” is an enclosure configured to hold or contain a dry powder formulation, a powder containing enclosure, and can be a structure with or without a lid.
• This container can be provided separately from the inhaler or can be structurally integrated within the inhaler (e.g. non-removable). Further, the container can be filled with a dry powder.
• a cartridge can also include a container.
• a "powder mass” refers to an agglomeration of powder particles or agglomerate having irregular geometries such as width, diameter, and length.
• microparticle refers to a particle with a diameter of about 0.5 to about 1000 ⁇ , irrespective of the precise exterior or interior structure. However four pulmonary delivery microparticles that are less than 10 ⁇ are generally desired, especially those with mean particles sizes of less than about 5.8 ⁇ in diameter.
• a dry powder formulation comprising, a peptide or a protein, wherein the peptide or protein is sensitive to degradation by heat.
• the dry powder formulation comprises a peptide including, oxytocin, an oxytocin derivative, or an oxytocin analog; a citrate, including; sodium citrate and zinc citrate; a divalent salt; including zinc chloride; calcium chloride and magnesium chloride; and one or more pharmaceutically acceptable carriers selected from sugars, for example, saccharides, disaccharides; oligosaccharides; an amino acid; wherein the sugar is, for example, trehalose, mannose, mannitol or sorbitol, and the carrier is polyethylene glycol, polyvinylpyrrolidone, or a diketopiperazine capable of forming microparticles, including, fumaryl diketopiperazine, succinyl diketopiperazine, maleyl d
• the formulation comprises a peptide, including, growth hormone, calcitonin, glucagon, parathyroid hormone, parathyroid hormone (1 -34), glucagon-like peptide-1 , interferon, interleukin, erythropoietin, luteinizing hormone-releasing hormone, somatostatin, vasopressin, enkephalin, adrenocorticotropic hormone, growth hormone-releasing hormone, growth factors, including, granulocyte colony formation-stimulating factor; thyroid stimulating hormone, thyroid-stimulating hormone-releasing hormone, antinociceptive peptides, angiotensin, prolactin, luteinizing hormone, rennin, gastric inhibitory polypeptide (GIP), and C-peptide.
• a peptide including, growth hormone, calcitonin, glucagon, parathyroid hormone, parathyroid hormone (1 -34), glucagon-like peptide-1 , interferon, interleukin,
• the formulation comprises a peptide, wherein the peptide is oxytocin, insulin, growth hormone, calcitonin, glucagon, parathyroid hormone, glucagon-like peptide-1 , glucagon like-peptide-2, parathyroid hormone (1 - 34), or parathyroid hormone releasing hormone, oxyntomodulin, peptide YY, leptin, deoxyribonuclease, ribonuclease, and follicle stimulating hormone.
• the peptide is oxytocin, insulin, growth hormone, calcitonin, glucagon, parathyroid hormone, glucagon-like peptide-1 , glucagon like-peptide-2, parathyroid hormone (1 - 34), or parathyroid hormone releasing hormone, oxyntomodulin, peptide YY, leptin, deoxyribonuclease, ribonuclease, and follicle stimulating hormone.
• the formulation comprises one or more peptides, one or more amino acid, wherein the amino acid is isoleucine, leucine, trileucine, cystine, cysteine, glycine, lysine, arginine, histidine, or methionine; and one or more sugars, including, lactose, mannitol, mannose, sorbitol, trehalose, and the like.
• the carrier can be polyethylene glycol, polyvinylpyrrolidone, or a saccharide, an oligosaccharide, or a polysaccharides, including lactose, trehalose, mannose, mannitol, or sorbitol; zinc citrate and zinc chloride; wherein the formulation is made by a spray-drying process wherein the peptide is in a buffered solution having a pH ranging from about pH 3.5 to about pH 7; or pH 4.5 to pH 6.5.
• the formulation comprises oxytocin in concentration from about 0.005 IU to about 40 IU, from 1 IU to about 15 IU; or from about 5 IU to about 20 IU.
• oxytocin is administered to a patient to prevent post-partum hemorrhaging a few minutes after giving birth in a formulation comprising oxytocin in an amount ranging from 5 to about 40 IU in a single inhalation.
• the content of oxytocin that can be provided in the formulation ranges from about 0.1 % (w/w) to about 50% (w/w), from about 0.5% (w/w) to about 40% (w/w); from about 0.5% (w/w) to about 20% (w/w); or from about 1 % (w/w) to about 10% (w/w).
• the amount of oxytocin can be greater than 40 IU depending in the need of the subject to be treated.
• a method for the effective delivery of a formulation to the blood stream of a subject comprising providing to a subject in need of treatment an inhalation system comprising an inhaler including a cartridge containing a formulation comprising a dry powder formulation comprising a peptide including, oxytocin, a citrate buffer or tartrate buffer and a divalent cation salt, wherein the divalent cation is zinc.
• the inhalation system delivers a powder plume comprising particles having a volumetric median geometric diameter (VMGD) less than 8 ⁇ .
• VMGD of the microparticles can range from about 4 ⁇ to 6 ⁇ .
• the VMGD of the powder particles can be from 3 ⁇ to about 6 ⁇ in a single inhalation of the formulation of fill mass ranging between 1 mg and 10 mg of dry powder.
• the inhalation system delivers greater than 40%; or greater than 60% of the dry powder formulation from the cartridge.
• the formulation is an amorphous dry powder comprising microparticles of disodium fumaryl diketopiperazine comprising oxytocin, a citrate buffer; zinc chloride, an amino acid, such as leucine, isoleucine, trileucine or cystine and mannitol or trehalose, or a combination thereof.
• the formulation comprises an amorphous dry powder comprising a peptide, including, a heat-sensitive peptide, including oxytocin; wherein the dry powder is formed by mixing oxytocin in a solution containing a citrate or acetate buffer at an adjusted pH ranging from 4.5 to 6.5 and adding a divalent cationic salt, including zinc chloride and optionally a sugar such as trehalose or mannitol prior to drying.
• the formulation comprises an amorphous dry powder comprising oxytocin; wherein the dry powder is formed by mixing oxytocin in a solution containing citrate salts and/or citric acid and adding a divalent cationic salt, including, zinc chloride and optionally a sugar such as trehalose or mannitol and optionally, one or more carriers.
• a divalent cationic salt including, zinc chloride and optionally a sugar such as trehalose or mannitol and optionally, one or more carriers.
• Further embodiments concern drug delivery systems comprising an inhaler, a unit dose dry powder medicament container, and a dry powder comprising a heat- sensitive peptide as disclosed herein and zinc citrate.
• One embodiment discloses a formulation comprising oxytocin, a derivative thereof, or an analog thereof, wherein the formulation further comprises diketopiperazine microparticles, including, microparticles of fumaryl diketopiperazine having a specific surface area (SSA) of less than about 67 m 2 /g.
• diketopiperazine microparticles in which the specific surface area is from about 35 to about 67 m 2 /g, within a 95% confidence limit.
• Another embodiment includes diketopiperazine microparticles in which the specific surface area is from about 35 to about 62 m 2 /g.
• the FDKP microparticles comprise a drug or active agent.
• the drug can be, for example, a peptide, including, oxytocin, insulin, glucagon-like peptide-1 (GLP-1 ), glucagon, exendin, parathyroid hormone, calcitonin, oxyntomodulin, derivatives and/or analogs thereof, and the like.
• the peptide content can vary depending on downstream processing conditions.
• the FDKP microparticles can be prepared to have a drug/peptide content that can vary depending on the dose to be targeted or delivered.
• the drug is insulin
• the insulin component can be from about 3 U/mg to about 6 U/mg in the powder formulation comprising the microparticles and the zinc salt and citrate can be added to solution prior to forming the particles.
• the drug is adsorbed to the surfaces of preformed microparticles.
• Further embodiments concern drug delivery systems comprising a combination of an inhaler, a unit dose dry powder medicament container, for example, a cartridge, and comprising the dry powder formulations disclosed herein and an active agent.
• the delivery system for use with the dry powders includes an inhalation system comprising a high resistance inhaler having air conduits which impart a high resistance to airflow through the conduits for deagglomerating and dispensing the powder.
• the inhalation system has a resistance value of, for example, approximately 0.065 to about 0.200 (VkPa)/liter per minute.
• the dry powders can be delivered effectively by inhalation with an inhalation system wherein the peak inhalation pressure differential can range from about 2 to about 20 kPa, which can produce resultant peak flow rates of about between 7 and 70 liters per minute.
• the inhalation system are configured to provide a single dose by discharging powder from the inhaler as a continuous flow, or as one or more pulses of powder delivered to a patient.
• the dry powder inhaler system comprises a predetermined mass flow balance within the inhaler.
• a flow balance of approximately 10% to 70% of the total flow exiting the inhaler and into the patient is delivered by one or more dispensing ports, which airflow passes through the area containing the powder formulation, and wherein approximately 30% to 90% air flow is generated from other conduits of the inhaler.
• bypass flow, or flow not entering and exiting the area of powder containment such as through a cartridge can recombine with the flow exiting the powder dispensing port within the inhaler to dilute, accelerate and ultimately deagglomerate the fluidized powder prior to exiting the mouthpiece.
• flow rates ranging from about 7 to 70 liters per minute result in greater than 75% of the container or the cartridge contents dispensed in fill masses between 1 mg and 50 mg; or 1 mg to 30 mg.
• an inhalation system as described above can emit a respirable fraction/fill of a powder dose at percentages greater than 40% in a single inhalation, greater than 50%, greater than 60%, or greater than 70%.
• an inhalation system comprising a dry powder inhaler, and a dry powder formulation.
• the dry powder formulation is provided in a unit dose cartridge.
• the dry powder formulation can be preloaded in the inhaler.
• the structural configuration of the inhalation system allows the deagglomeration mechanism of the inhaler to produce respirable fractions greater than 50%; that is, more than half of the powder contained in the inhaler (cartridge) is emitted as particles of less than 5.8 ⁇ .
• the inhalers can discharge greater than 85% of a powder medicament contained within a container during dosing.
• the inhalers can discharge greater than 85% of a powder medicament contained in a single inhalation. In one embodiment, the inhalers can discharge greater that 90% of the cartridge contents or container contents in less than 3 seconds at pressure differentials between 2 and 5 kPa with fill masses ranging up to 30 mg.
• Another embodiment disclosed herein includes a method of making microparticles suitable for pulmonary administration as a dry powder formulation comprising, a carrier particle, including, diketopiperazine microparticles.
• the dry powder formulation is obtained by spray-drying a solution containing a peptide, wherein the one or more excipients is dissolved in an aqueous solution comprising the zinc salt and citrate and mixed, followed by adding the amount of the peptide with mixing to form a feed solution; atomizing the flow of solution into a drying nitrogen gas flow at an inlet temperature of about 120 °C to 150 °C and an outlet temperature of about 60°C to 65°C, or 50 °C to 75 °C, or 40 °C to 85 °C, or the like.
• the method of making diketopiperazine microparticles having the specific surface area of less than about 67 m 2 /g, and/or a trans isomer ratio of about 45% to 65% which utilizes a diketopiperazine having the formula 2,5- diketo-3,6-bis(A/-X-4-aminobutyl)piperazine disodium salt or magnesium salt, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl.
• the diketopiperazine has the formula (bis— 3,6-(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine or 2,5-diketo-3,6-bis(A/-fumaryl-4- amino-butyl)piperazine.
• Another embodiment disclosed herein includes a method of delivering a drug, for example, a peptide such as insulin to a patient in need thereof comprising administering a dry powder to the deep lung by inhalation of the dry powder by the patient; wherein the dry powder comprises diketopiperazine microparticles comprising insulin, a zinc salt and citrate; wherein the microparticles are formed of a diketopiperazine and have a SSA ranging from about 35 to about 67 m 2 /g or about 40 to about 67 m 2 /g and/or in microparticles having a trans isomer content raging from about 45% to about 65%.
• a drug for example, a peptide such as insulin
• the dry powder comprises diketopiperazine microparticles comprising insulin, a zinc salt and citrate; wherein the microparticles are formed of a diketopiperazine and have a SSA ranging from about 35 to about 67 m 2 /g or
• an insulin-related disorder can specifically include or exclude any or all of pre-diabetes, type 1 diabetes mellitus (honeymoon phase, post-honeymoon phase, or both), type 2 diabetes mellitus, gestational diabetes, hypoglycemia, hyperglycemia, insulin resistance, secretory dysfunction, impaired early-phase release of insulin, loss of pancreatic ⁇ -cell function, loss of pancreatic ⁇ -cells, and metabolic disorder.
• One embodiment comprises a method of treating an endocrine-related disease or disorder comprising administering to a person in need thereof a dry powder formulation comprising a peptide hormone, including, oxytocin, GLP-1 and the like, citrate and a divalent cationic salt.
• the dry powder formulation can comprise disodium FDKP microparticles or FDKP microparticles having a specific surface area of less than about 67 m 2 /g and a drug suitable to treat said disease or disorder.
• the method can comprise administering to a subject a dry powder formulation.
• a hormone-related disorder such as postpartum hemorrhage, or any other oxytoc
• the formulation comprising insulin the subject to be treated can specifically include or exclude any or all of pre-diabetes, type 1 diabetes mellitus (honeymoon phase, post-honeymoon phase, or both), type 2 diabetes mellitus, gestational diabetes, hypoglycemia, hyperglycemia, insulin resistance, secretory dysfunction, impaired early-phase release of insulin, loss of pancreatic ⁇ -cell function, loss of pancreatic ⁇ -cells, and metabolic disorder.
• the dry powder comprises insulin.
• the dry powder comprises glucagon, an exendin, or GLP-1 , PTH, PTHrP, combinations thereof, and the like.
• specific RF/fill values can depend on the inhaler used to deliver the powder. Powders generally tend to agglomerate and crystalline DKP microparticles form particularly cohesive powders.
• One of the functions of a dry powder inhaler is to deagglomerate the powder so that the resultant particles comprise a respirable fraction suitable for delivering a dose by inhalation.
• deagglomeration of cohesive powders is typically incomplete so that the particle size distribution seen when measuring the respirable fraction as delivered by an inhaler will not match the size distribution of the primary particles, that is, the profile will be shifted toward larger particles.
• Inhaler designs vary in their efficiency of deagglomeration and thus the absolute value of RF/fill observed using different designs will also vary. However, optimal RF/fill as a function of specific surface area will be similar from inhaler to inhaler.
• 2,5-Diketopiperazines can be formed into microparticles that incorporate a drug or microparticles onto which a drug can be adsorbed.
• the combination of a drug and a diketopiperazine can impart improved drug stability and/or absorption characteristics.
• These microparticles can be administered by various routes of administration. As dry powders these microparticles can be delivered by inhalation to specific areas of the respiratory system, including the lungs.
• microparticles are typically obtained by pH-based precipitation of the free acid (or base) resulting in self-assembled microparticles comprised of aggregated crystalline plates.
• the stability of the particle can be enhanced by small amounts of a surfactant, such as polysorbate-80, in the DKP solution from which the particles are precipitated (see for example US Patent Publication No. 2007/0059373 entitled “Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents" which is incorporated herein by reference in its entirety for all that it teaches regarding the formation and loading of DKP microparticles and dry powders thereof).
• solvent can be removed to obtain a dry powder.
• Appropriate methods of solvent removal include lyophilization and spray drying (see for example US Patent Publication No. 2007/0196503 entitled “A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent” and U.S. Patent No. 6,444,226 entitled “Purification and stabilization of peptide and protein pharmaceutical agents” each of which is incorporated herein by reference in its entirety for all that it teaches regarding the formation and loading of DKP microparticles and dry powders thereof).
• the microparticles disclosed herein can be composed of DKP free acid or bases or composed of DKP salts.
• Such particles are typically formed (as opposed to dried) by spray drying, resulting in spheres and/or collapsed spheres of an amorphous salt (as opposed to a free acid or base) so that they are chemically, physically, and morphologically distinct entities.
• the present disclosure refers to FDKP as the free acid or the dissolved anion.
• an exemplary embodiment includes the disodium salt of FDKP or FDKP disodium salt as disclosed and contemplated in U.S. Patents Nos. 7,820,676 and 8,278,308, which are incorporated herein by reference in its entirety.
• lysine anhydride can also be prepared via cyclodimerization of ⁇ - ⁇ - ⁇ -L-lysine in molten phenol, similar to the Kopple method, followed by removal of the blocking (P)-groups with an appropriate reagent and conditions.
• P blocking
• CBz-protecting groups can be removed using 4.3 M HBr in acetic acid.
• This route can be preferred because it uses a commercially available starting material, it involves reaction conditions that are reported to preserve stereochemistry of the starting materials in the product and all steps can be easily scaled up for manufacture.
• Methods for synthesizing diketopiperazines are also described in U.S. Patent No. 7,709,639, entitled, "Catalysis of Diketopiperazine Synthesis," which is also incorporated by reference herein for its teachings regarding the same.
• Fumaryl diketopiperazine bis— 3,6-(N-fumaryl-4-aminobutyl)-2,5-diketo- diketopiperazine; FDKP
• FDKP diketopiperazine
• FDKP provides a beneficial microparticle matrix because it has low solubility in acid but is readily soluble at neutral or basic pH. These properties allow FDKP to crystallize and the crystals to self-assemble into form microparticles under acidic conditions. The particles dissolve readily under physiological conditions where the pH is neutral. As noted, microparticles having a diameter of between about 0.5 and about 10 microns can reach the lungs, successfully passing most of the natural barriers. Particles in this size range can be readily prepared from FDKP.
• microparticles having a diameter of between about 0.5 and about 10 microns can reach the lungs, successfully passing most of the natural barriers.
• Particles in this size range can be readily prepared from diketopiperazines with acidic groups, such as the carboxylate groups in FDKP (as well as in related molecules such as 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine wherein X is succinyl, glutaryl, or maleyl).
• acid precipitation self-assembled particles composed of aggregates of crystalline plates are obtained.
• the size of these plates relates to the specific surface area of the particles which in turn is implicated in effects on the structure, loading capacity, and aerodynamic performance of the particles.
• the SSA of DKP microparticles is a measure of average crystal size and can be used to gauge the relative contributions of crystal nucleation and growth to microparticle characteristics. SSA depends on the size of microparticle crystals and the density (p) of the microparticle matrix and is inversely proportional to the characteristic size, L, of the crystals.
• Embodiments disclosed herein show that microparticles with a specific surface area less than about 67 m 2 /g exhibit characteristics beneficial to delivery of drugs to the lungs such as improved aerodynamic performance with moderately efficient inhalers such as the MEDTONE® inhaler disclosed in U.S. Patent No.
• Patent No.8, 499, 757 entitled, “A Dry Powder Inhaler and System for Drug Delivery,” filed on June 12, 2009
• U.S. Patent Application No. 12/717,884 now U.S. Patent No. 8,485,180, entitled, “Improved Dry Powder Drug Delivery System,” filed on March 4, 2010, which disclosures are herein incorporated by reference for its teachings regarding the same.
• the first step in the manufacture of FDKP microparticles is the formation of the microparticles by pH-induced crystallization of FDKP and the self-assembly of the FDKP crystals into microparticles having an overall spherical morphology (Fig. 2). Accordingly, the manufacture of microparticles is essentially a crystallization process. Excess solvent can be removed by washing the suspension by repeated centrifugation, decantation and re-suspension, or by diafiltration.
• insulin can be adsorbed directly onto the microparticles while in suspension (i.e. prior to freeze drying) by adding an insulin stock solution to the FDKP microparticle suspension comprising a citrate buffer.
• a pH control step can also be performed after the addition of the insulin stock solution. This step can promote insulin adsorption onto the microparticles in suspension prior to further processing. Increasing the pH of the suspension to about 4.5 promotes complete insulin adsorption onto the microparticles in suspension without excessive dissolution of the FDKP from the particle matrix and also improves the stability of insulin in the bulk drug product.
• the suspension can be flash-frozen drop-wise (i.e. cryo-pelletized) in liquid nitrogen and lyophilized to remove the solvent and obtain a dry powder. In alternative embodiments the suspension can be spray-dried to obtain the dry powder.
• a manufacturing process for making the present FDKP microparticles containing insulin is provided.
• a high shear mixer such as a Dual-feed SONOLATORTM at 2000 psi through a 0.001 -in 2 orifice, or for example, the high shear mixer as disclosed in U.S. Provisional Patent Application Serial No.
• DKP microparticlesparticles equal masses of about 10.5 wt% acetic acid and about 2.5 wt% FDKP solutions at about 16°C ⁇ about 2°C can be fed at 2000 psi through a 0.001 -in 2 orifice.
• the precipitate can be collected in a deionized (Dl) water reservoir of about equal mass and temperature.
• the resultant suspension comprises about 0.8% solids.
• the precipitate can be concentrated and washed by tangential flow filtration. The precipitate can be first concentrated to about 4% solids then washed with deionized water.
• the suspension can be finally concentrated to about 10% solids based on the initial mass of FDKP.
• the concentrated suspension can be assayed for solids content by an oven drying method.
• the FDKP microparticles in suspension are homogenized with zinc and citrate solution containing the insulin to form the powder particles then sprayed dried or lyophilized.
• active agent used interchangeably with “drug” refers to pharmaceutical substances, including small molecule pharmaceuticals, biologicals and bioactive agents.
• Active agents can be naturally occurring, recombinant or of synthetic origin, including proteins, polypeptides, peptides, nucleic acids, organic macromolecules, synthetic organic compounds, polysaccharides and other sugars, fatty acids, and lipids, and antibodies and fragments thereof, including, but not limited to, humanized or chimeric antibodies, F(ab), F(ab) 2 , a single-chain antibody alone or fused to other polypeptides or therapeutic or diagnostic monoclonal antibodies to cancer antigens.
• the active agents can fall under a variety of biological activity and classes, such as vasoactive agents, neuroactive agents, hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antiviral agents, antigens, infectious agents, inflammatory mediators, hormones, and cell surface antigens.
• active agents can include, in a non-limiting manner, cytokines, lipokines, enkephalins, alkynes, cyclosporins, anti-IL-8 antibodies, IL-8 antagonists including ABX-IL-8; prostaglandins including PG-12, LTB receptor blockers including LY2931 1 , BIIL 284 and CP105696; triptans such as sumatriptan and palmitoleate, insulin and analogs thereof, growth hormone and analogs thereof, parathyroid hormone (PTH) and analogs thereof, parathyroid hormone related peptide (PTHrP), ghrelin, obestatin, enterostatin, granulocyte macrophage colony stimulating factor (GM-CSF), amylin, amylin analogs, glucagon- like peptide 1 (GLP-1 ), Texas Red, clopidogrel, PPACK (D-phenylalanyl-L-prolyl-L- arginine chloromethyl cytok
• the drug content to be delivered depends on the need of the subject and the potency of the drug.
• microparticles formed from FDKP having a trans isomer content between 45% and 65% is typically greater than 0.01 % are used.
• the drug content to be delivered with the microparticles having the aforementioned trans isomer content can range from about 0.01 % to about 20%, which is typical for peptides such as insulin.
• the present microparticles typically comprise 3-6 U/mg (approximately 10 to 15%) insulin.
• the drug content of the particles can vary depending on the form and size of the drug to be delivered.
• the range of loading of the drug to be delivered is typically between about 0.01 % and about 90%, depending on the form and size of the drug to be delivered and the potency of the dose required.
• preferred loads are about 0.5% to about 50% (w/w); or from about 0.5 % (w/w) to about 20% (w/w).
• DKP microparticles described herein retain the required isomer content, they can adopt other additional characteristics beneficial for delivery to the lung and/or drug adsorption.
• U.S. Patent No. 6,428,771 entitled “Method for Drug Delivery to the Pulmonary System” describes DKP particle delivery to the lung and is incorporated by reference herein for its teachings regarding the same.
• U.S. Patent No. 6,444,226, entitled, "Purification and Stabilization of Peptide and Protein Pharmaceutical Agents” describes beneficial methods for adsorbing drugs onto microparticle surfaces and is also incorporated by reference herein for its teachings regarding the same. Microparticle surface properties can be manipulated to achieve desired characteristics as described in U.S. Patent Application No.
• Samples of the incubated material were taken at various times after onset of the experiments and up to approximately 7 months.
• the samples were evaluated by high performance liquid chromatography (HPLC) assay (see preparation described below) to determine the presence of the oxytocin in the samples and the degradation products.
• Oxytocin stability studies were performed up to 1 1 months for certain powders, including, Sample ID Nos. 4, 6 and 13 in Table 2.
• Spray-dried powders were prepared with a target oxytocin content of 1 %. Formulation contents are detailed in Table 2.
• a mixture having a ratio of 87:10:2 by weight of trehalose, isoleucine and PVP served as a matrix for control formulations of Samples ID Nos. 1 to 6.
• To this mixture were added sodium citrate and zinc.
• the quantities of citrate salts were varied from 100 to 20 equivalents per mole of oxytocin (24 to 4.8% of total weight).
• the quantities of the zinc salts were varied from 50 to 10 equivalents per mole of oxytocin (6.7 to 1 .3% of total weight).
• Concentrated sodium citrate buffers 75 mM pH 4.5 and 6.5) were used as the source of citrate.
• the oxytocin stability study results from are shown in Table 4 below.
• the data is shown as the percent (%) of oxytocin remaining in the sample compared to the starting amount of material used.
• three of the powder formulations (Sample ID Nos. 4, 6, and 13) tested maintained more than about 90% of the oxytocin as assayed after 32 weeks of incubation.
• the data also show that the combination of sodium citrate and zinc salt led to the highest stability (less degradation of oxytocin) in solid or dry powder form (about 100%, Sample ID No. 6).
• SEM Scanning electron micrographs
• LOD Loss on drying
• Aerodynamic performance of the spray-dried powders was measured by Andersen Cascade Impaction with the Gen2C inhaler (30 Lpm, 8s, MannKind Corp.) and the results are shown in Table 5.
• Geometric particle size was determined by laser diffraction using a Sympatec RODOS M powder disperser set at 0.5 bar and 3 bar dispersing pressures. Particle morphology was assessed by field emission scanning electron microscopy. Table 5 shows that particles range in size from about 3.8 to 5.6 ⁇ at 0.5 bar and 3 bar atmospheric pressures tested and had a %RF/fill of about 40 to about 60%.
• Table 5 shows that particles range in size from about 3.8 to 5.6 ⁇ at 0.5 bar and 3 bar atmospheric pressures tested and had a %RF/fill of about 40 to about 60%.
• the samples containing citrate and zinc Sample ID No.
• Oxytocin content was evaluated using an HPLC method.
• Oxytocin standard solutions were prepared at approximately 250 ⁇ g/mL in 0.1 M sodium bicarbonate pH 9.5 (6.25 mg of oxytocin raw material in 25.0 mL). Powders were prepared by dissolving 10 ⁇ 1 .0 mg in 0.1 M sodium bicarbonate pH 9.5 to give a final oxytocin concentration of 0.250 mg/mL. Initial drug content was assayed to ascertain the starting material. Powders were prepared with a target drug content of 1 % and assays confirmed the oxytocin content between 0.92 and 1 .13%.
• the powders were weighed into 20 mL glass vials that were then closed, wrapped in foil, and heat sealed.
• the foil pouches were placed on a stability chamber at 40°C/75% RH. Samples were pulled at 2 and 4 weeks; then pulled every 4 weeks and up to 32 weeks after incubation. Samples were stored frozen (-20 °C) until assayed by HPLC as discussed above.
• Particle morphology studied by scanning electron microscopy shows that spray-drying of the control formulation (Sample ID No. 1 ) containing trehalose, PVP and isoleucine produced slightly corrugated, spherical particles typical of leucine- containing powders (FIG. 2A).
• the corrugated substantially spherical morphology was maintained with the addition of salts (zinc and citrate salts) to the mixture containing trehalose, PVP and isoleucine (FIGs. 2B; 2C and 2D).
• the particles containing zinc and citrate differ from the controls as they appear slightly more corrugated and less spherical.
• the particles formed with zinc and/or citrate appear substantially spherical and have a slightly more indentations, corrugated surface or wrinkle appearance, and less regular pattern. It was observed that the particles containing oxytocin, zinc and citrate appeared to be more fragile or more collapsible than the controls during preparation in particular during vacuum drying step.
• FIG. 4 provides a graphic representation of data obtained from X-ray diffraction studies of dry powders showing amorphous content of the powders by their characteristic scan patterns. The data demonstrates that the X-ray diffraction analysis confirmed that the spray-dried powders all appear as uniform amorphous in content as demonstrated by data scans depicted in FIG. 4.
• the data also demonstrates that the addition of citrate/zinc to a powder containing FDKP (Sample ID No. 7) (19.5% w/w), trehalose (38.4% w/w) and isoleucine (6.5% w/w) produced a powder with improved properties (42% RF/fill) over the powder without citrate and zinc.
• the powder containing citrate yielded a 17% improvement in RF/fill over a powder formulated without citrate/zinc (25.6% RF/fill, 78.4% CE).
• the present powders were not excessively cohesive because their median geometric particle sizes were similar at 0.5 bar and 3 bar RODOS dispersing pressures. The average values were 4.34 and 4.18 ⁇ at 0.5 and 3 bars.
• Table 5 show the aerodynamic performance of the powders. Table 5 shows that the powders containing citrate and zinc yielded high respirable fractions (>70%) and cartridge emptying data in some instances were greater than >90% (data not shown). Sample testing in an anatomically correct airway model showed that about 73% of the dose in an inhaler containing the powders is delivered to the lungs.
• Example 2 Unlike in Example 1 , bulk solid sodium citrate salt and citric acid were used as source of sodium citrate. Samples containing 1 % (w/w) oxytocin were made as described in Example 1 and the solutions or suspensions were then spray-dried using the parameters as described in Table 6 below.
• Spray-dried powders containing a target oxytocin content of 1 % were assayed and the data confirmed the oxytocin values ranged between 0.87 to 1 .01 %.
• the components of the prepared formulations are detailed in Table 7 showing the contents of each sample made and tested.
• a mixture having a ratio of 87:10:2 by weight of trehalose, isoleucine and PVP served as a matrix for all the formulations except samples ID No. 20 and 21 .
• sodium citrate, citric acid and zinc were added.
• the quantities of citrate salts were varied from 100 to 50 equivalents per mole of oxytocin (29.2 to 14.6% of total weight).
• the quantities of the zinc salts were varied from 50 to 5 equivalents per mole of oxytocin (30.3 to 0.7% of total weight).
• the zinc cation appeared to be essential to the composition characteristics as exemplified by zinc chloride use alone (Sample ID No. 22) also provided improved stability of the powders.
• Aerodynamic performance of the spray-dried powders was measured by Andersen Cascade Impaction with the Gen2C inhaler (21 .6 Lpm, 4s, MannKind Corp.) and the results are shown in Table 8.
• High %Rf/fill (> 50%) were obtained even under a low peak inspiratory pressure.
• the data in Table 8 Shows the % RF/fill ranging from about 20 to about 60% and cartridge emptying of total contents was up to 77% (Sample ID No. 22).
• the highest %Rf/Fill were obtained for powders containing zinc citrate, zinc chloride with or without PVP.
• %Rf/fill was improved by the addition of isoleucine (Sample ID Nos. 14 and 20).
• the samples containing zinc citrate or zinc chloride alone had high %Rf/fill of about 50 to 60% and cartridge emptying greater than 70%.
• Aerodynamic testing on selected powders highlighted the beneficial effect of combining sodium citrate and zinc chloride with trehalose, isoleucine with or without PVP as exemplified by Sample ID No. 18, 19, 20 and 21 .
• the improved performance of the powders was observed with citrate and zinc contents as low as 14.6% and 1 .4% respectively (Sample ID Nos. 16 and 18).
• the maximum effect (53.0% RF/fill) was obtained with 14.6% content in sodium citrate and 6.8% in zinc (Sample ID No. 18).
• the beneficial effect of combining zinc citrate with trehalose, isoleucine and PVP is exemplified by the performance of powders Sample ID Nos. 23 and 24, which yielded % Rf/fill greater than 50% and cartridge emptying of about 73%.
• Example 1 Stability of oxytocin spray-dried powders was performed as in Example 1 above. Stability testing was performed up to 40 weeks. The oxytocin stability study results from the assays are shown in Table 9 below and FIG. 5. The data is shown as the percent (%) remaining of sample compared to the starting material used. As seen in Table 9, only 3 of the powder formulations (Sample ID Nos. 16, 27, and 28) tested maintained less than about 90% of the oxytocin when aliquots of the sample were assayed after 40 weeks incubation. The combination of citrate and zinc salts led to the highest stability in solid state (greater than about 90%). The highest stability was achieved with the combination containing 14.6% sodium citrate and 6.8% zinc chloride (Sample ID No. 18).
• FIG. 5 is a graphic representation of dry powder samples from the stability studies wherein the samples containing divalent zinc salt and citrate salts at various concentrations showed a slow degradation of the oxytocin over a period of 40 weeks; wherein the samples tested retained greater than 90% of the oxytocin content.
• powders containing zinc and tartrate salts maintained also about 90% of the oxytocin content after 24 weeks of incubation and greater than 85% of the oxytocin content after 32 weeks of sample incubation.
• a pregnant woman, 35 year old and in her second pregnancy has a history of mild post-partum hemorrhaging in her first pregnancy is admitted to the hospital at 40 weeks of pregnancy and in labor. Contractions are monitor to occur 5 minutes apart by the attending obstetrician.
• the pregnant woman is noted to be bleeding and delivers a healthy baby.
• the woman is administered by oral inhalation a dry powder formulation containing a single dose of 100 IU of oxytocin, 28% (w/w) citrate and 7% (w/w) zinc chloride, in a single inhalation, using an inhalation system comprising a high resistance inhaler as described in U.S. Patent No. 8,484,129, which disclosure is incorporated herein by reference in its entirety for its teaching of the relevant subject matter.
• the woman was kept in the hospital for 3 days and did not suffer any severe bleeding and was released with her newborn baby.

Priority Applications (19)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=51352762

Family Applications (1)

Country Status (10)

Cited By (29)

Families Citing this family (8)

Citations (6)

Family Cites Families (1121)